Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04036292 |
|
Recruitment Status :
Completed
First Posted : July 29, 2019
Results First Posted : November 22, 2021
Last Update Posted : November 22, 2021
|
Sponsor:
Oyster Point Pharma, Inc.
Information provided by (Responsible Party):
Oyster Point Pharma, Inc.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Dry Eye Disease (DED) | Drug: OC-01 (varenicline) nasal spray Drug: Placebo (vehicle) nasal spray | Phase 3 |
This was a Phase 3, multicenter, randomized, controlled, double-masked (including subjects, Investigators, study site personnel, and Sponsor personnel) study designed to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray 0.6 mg/mL and 1.2 mg/mL in adult participants with DED. The study randomized 758 subjects at least 22 years of age with a physicians' diagnosis of DED and meeting all other study eligibility criteria to receive OC-01 (varenicline) nasal spray or placebo twice daily (BID) for 28 days with three additional long-term follow-up visits at 6 weeks, 6 months, and 12 months. Participants who terminated from the study during the treatment period were asked to complete safety assessments (if the participants agree) prior to study exit. Participants who were terminated early from the study were not replaced
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 758 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease (The ONSET-2 Study) |
| Actual Study Start Date : | July 23, 2019 |
| Actual Primary Completion Date : | April 10, 2020 |
| Actual Study Completion Date : | February 5, 2021 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Eye Diseases
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: OC-01 Low Dose, 0.6 mg/mL
OC-01 (varenicline) nasal spray, 0.6 mg/ML
|
Drug: OC-01 (varenicline) nasal spray
OC-01 (varenicline) nasal spray |
|
Active Comparator: OC-01 High Dose, 1.2 mg/mL
OC-01 (varenicline) nasal spray, 1.2 mg/ML
|
Drug: OC-01 (varenicline) nasal spray
OC-01 (varenicline) nasal spray |
|
Placebo Comparator: Placebo (vehicle) nasal spray
Placebo (vehicle) nasal spray
|
Drug: Placebo (vehicle) nasal spray
Placebo (vehicle) nasal spray |
Primary Outcome Measures :
- Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28) [ Time Frame: 28 Days [Visit 1 (baseline) and Visit 4b (28 days)] ]The primary endpoint was the percentage of subjects who achieve ≥10 mm improvement in Schirmer's Test Score from baseline to 28 days in the study eye following treatment with OC-01. Schirmer's test scores from 0-35 mm where a higher score is indicative of a better outcome.
Secondary Outcome Measures :
- Mean Change From Baseline in Eye Dryness Score in CAE at Week 4 at 5 Minutes [ Time Frame: 28 Days [Visit 1 (baseline) and Visit 4a (28 days)] ]Change in Eye Dryness Score Eye from baseline in CAE at 4 Weeks at 5 minutes post treatment. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.
- Mean Change From Baseline in Eye Dryness Score From Baseline to Day 28 [ Time Frame: 28 Days [Visit 1 (baseline) and Visit 4b (28 days)] ]Change in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.
- Mean Change Form Baseline in Schirmer's Test Score From Baseline to Day 28 [ Time Frame: 28 Days [Visit 1 (baseline) and Visit 4b (28 days)] ]Change in Schirmer test score from baseline to Day 28. Schirmer's test scores from 0-35 mm where a higher score is indicative of a better outcome.
- Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 2 [ Time Frame: 14 Days [Visit 1 (baseline) and Visit 3 (14 days)] ]Chang in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better otucome.
- Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 1 [ Time Frame: 7 Days [Visit 1 (baseline) and Visit 2 (7 days)] ]Change in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 22 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Have used and/or desired to use an artificial tear substitute for dry eye symptoms within 6 months prior to Visit 1
Exclusion Criteria:
- Have had any intraocular surgery (such as cataract surgery) or extraocular surgery in either eye within three months or refractive surgery (e.g. laser-assisted in-situ keratomileusis, laser epithelial keratomileusis, photorefractive keratectomy or corneal implant) within twelve months of Visit 1.
- Have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with dry eye disease are allowed.
- Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
- Have a known hypersensitivity to any of the procedural agents or study drug components
- Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04036292
Locations
Show 22 study locations
Sponsors and Collaborators
Oyster Point Pharma, Inc.
Study Documents (Full-Text)
Documents provided by Oyster Point Pharma, Inc.:
Documents provided by Oyster Point Pharma, Inc.:
Study Protocol [PDF] September 18, 2019
Statistical Analysis Plan [PDF] April 29, 2020
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Oyster Point Pharma, Inc. |
| ClinicalTrials.gov Identifier: | NCT04036292 |
| Other Study ID Numbers: |
OPP-101 |
| First Posted: | July 29, 2019 Key Record Dates |
| Results First Posted: | November 22, 2021 |
| Last Update Posted: | November 22, 2021 |
| Last Verified: | August 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Dry Eye Syndromes Keratoconjunctivitis Sicca Eye Diseases Lacrimal Apparatus Diseases Keratoconjunctivitis Conjunctivitis Conjunctival Diseases Keratitis |
Corneal Diseases Varenicline Nicotinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |